Panacea Biotec quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	200	167	+19.7%
EBITDA	5.7	−1.2	—
EBITDA margin	2.8%	−0.7%	+3.6 pts
Profit before tax	3.6	6.6	−45.6%
Net profit	2.2	4.0	−44.4%
EPS	₹0.38	₹0.66	−42.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	200	167	165	141	167	133	163	147	116	136	151	143	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	4.2	2.6	2.3	6.4	5.7	8.6	3.6	4.7	3.8	10.8	5.7	3.2
	204	169	167	148	172	141	167	152	120	147	156	146
	74.2	80.8	90.2	46.6	72.7	83.3	48.7	41.8	40.2	45.5	47.8	59.8
	0.8	2.7	2.4	1.9	2.0	7.5	0.2	0.0	0.0	−0.5	1.1	0.0
	26.8	−7.1	−24.6	10.5	2.5	−38.7	13.7	1.4	1.5	4.7	18.4	−1.6
	44.2	46.8	40.5	47.7	45.7	49.1	43.0	43.4	37.5	38.4	37.7	37.5
	1.2	1.2	1.9	2.1	0.9	1.0	1.0	1.0	0.9	0.8	0.9	0.9
	7.9	7.9	8.5	8.3	8.4	8.4	9.0	8.7	8.7	8.8	9.1	9.3
	48.0	41.0	45.0	52.3	44.9	58.2	50.0	53.7	50.5	54.3	45.7	50.9
	203	173	164	169	177	169	166	150	139	152	161	157
	5.7	2.6	11.7	−17.8	−1.2	−26.9	8.0	7.0	−14.0	−6.0	−0.2	−3.6
	−2.2	−5.3	3.3	−26.1	−9.6	−35.3	−1.0	−1.7	−22.7	−14.9	−9.3	−12.9
Profit
	0.8	−4.0	3.7	−21.9	−4.8	−27.8	1.6	2.0	−19.8	−4.9	−4.4	−10.6
	2.7	2.7	2.8	2.7	11.3	27.7	2.8	2.8	2.7	2.7	2.8	2.8
	3.6	−1.3	6.5	−19.2	6.6	−0.0	4.4	4.8	−17.1	−2.1	−1.7	−7.8
	0.4	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.0
	1.0	−0.6	2.6	−5.2	2.6	1.9	−0.1	0.1	−1.2	−0.2	−0.1	0.5
	1.4	−0.3	2.6	−5.2	2.6	2.0	−0.1	0.1	−1.2	−0.1	0.6	0.5
	2.2	−1.0	3.9	−14.0	4.0	−2.0	4.4	4.7	−15.9	−2.0	−2.2	−8.3
	2.2	−1.0	3.9	−14.0	4.0	−2.0	4.4	4.7	−15.9	−2.0	−2.2	−8.3
	0.4	5.0	0.5	−0.0	−0.0	1.4	−0.1	−0.2	0.0	−0.7	0.1	0.1
	2.6	4.0	4.4	−14.0	3.9	−0.6	4.4	4.5	−15.9	−2.7	−2.1	−8.2
	2.3	0.5	4.0	−13.9	4.1	−1.9	4.5	4.8	−15.8	−1.4	—	−8.3
	−0.1	−1.5	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	−0.6	—	0.0
Per share
	₹0.38	₹0.08	₹0.65	−₹2.27	₹0.66	−₹0.31	₹0.74	₹0.77	−₹2.59	−₹0.23	−₹0.37	−₹1.35
	₹0.38	₹0.08	₹0.65	−₹2.27	₹0.66	−₹0.31	₹0.74	₹0.77	−₹2.59	−₹0.23	−₹0.37	−₹1.35
Other comprehensive income — detail
	0.4	5.0	0.5	−0.0	−0.0	1.4	—	—	—	—	—	—
	0.5	1.5	0.6	−0.0	−0.0	0.3	−0.1	−0.1	−0.1	−0.9	0.1	0.2
	0.1	0.4	0.2	0.0	−0.0	0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.0	−0.2	0.0	0.0
	0.0	3.9	—	—	—	1.2	—	−0.1	0.1	−0.1	0.0	0.0
	2.7	5.5	4.4	−13.9	4.0	−0.5	4.4	4.6	−15.8	−2.1	−2.2	−8.3
	−0.1	−1.5	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	−0.1	−0.6	0.1	0.1
Per share — as-filed variants
	₹0.38	₹0.08	₹0.65	−₹2.27	₹0.66	−₹0.31	₹0.74	₹0.77	−₹2.59	−₹0.23	−₹0.37	−₹1.35
	₹0.38	₹0.08	₹0.65	−₹2.27	₹0.66	−₹0.31	₹0.74	₹0.77	−₹2.59	−₹0.23	−₹0.37	−₹1.35
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	97.9	90.4	97.3	82.2	89.5	80.5	101	104	74.0	86.7	83.2	84.8
	49.0%	54.2%	58.9%	58.2%	53.7%	60.7%	61.7%	70.7%	63.9%	63.5%	55.3%	59.3%
Adjusted (ex-exceptional items) — derived
	0.8	−4.0	3.7	−21.9	−4.8	−27.8	1.6	2.0	−19.8	−4.9	−4.4	−10.6
	2.7	2.7	2.8	2.7	11.3	27.7	2.8	2.8	2.7	2.7	2.8	2.8
	0.5	−3.2	2.2	−16.0	−2.9	−29.7	1.7	2.0	−18.4	−4.6	−5.0	−11.1
	₹0.09	₹0.25	₹0.37	−₹2.59	−₹0.48	−₹4.63	₹0.28	₹0.32	−₹3.01	−₹0.53	−₹0.84	−₹1.80

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

PANACEABIO₹329.05

Panacea Biotec Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSAIPARENT HIKAL INDOCO DCAL WINDLAS HESTERBIO SOLARA SYNCOMFMcap ₹2,017 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	143.0	150.5	136.5	115.7	147.4	163.5	132.5	166.7	141.1	165.2	166.8	199.6
Other Income	3.2	5.7	10.8	3.8	4.7	3.6	8.6	5.7	6.4	2.3	2.6	4.2
Total Income	146.3	156.2	147.3	119.5	152.0	167.1	141.1	172.4	147.5	167.5	169.3	203.8
Expenses
+ Cost of Materials Consumed	59.8	47.8	45.5	40.2	41.8	48.7	83.3	72.7	46.6	90.2	80.8	74.2
+ Purchases of Stock-in-Trade	0.0	1.1	-0.5	0.0	0.0	0.2	7.5	2.0	1.9	2.4	2.7	0.8
+ Changes in Inventories	-1.6	18.4	4.7	1.5	1.4	13.7	-38.7	2.5	10.5	-24.6	-7.1	26.8
+ Employee Benefit Expense	37.5	37.7	38.4	37.5	43.4	43.0	49.1	45.7	47.7	40.5	46.8	44.2
+ Finance Costs	0.9	0.9	0.8	0.9	1.0	1.0	1.0	0.9	2.1	1.9	1.2	1.2
+ Depreciation & Amortisation	9.3	9.1	8.8	8.7	8.7	9.0	8.4	8.4	8.3	8.5	7.9	7.9
+ Other Expenses	50.9	45.7	54.3	50.5	53.7	50.0	58.2	44.9	52.3	45.0	41.0	48.0
Total Expenses	156.8	160.6	152.1	139.3	150.0	165.5	168.9	177.1	169.4	163.8	173.3	203.0
EBITDA	-3.6	-0.2	-6.0	-14.0	7.0	8.0	-26.9	-1.2	-17.8	11.7	2.6	5.7
EBIT	-12.9	-9.3	-14.9	-22.7	-1.7	-1.0	-35.3	-9.6	-26.1	3.3	-5.3	-2.2
Profit
PBT before Exceptional Items	-10.6	-4.4	-4.9	-19.8	2.0	1.6	-27.8	-4.8	-21.9	3.7	-4.0	0.8
+ Exceptional Items	2.8	2.8	2.7	2.7	2.8	2.8	27.7	11.3	2.7	2.8	2.7	2.7
Pretax Income	-7.8	-1.7	-2.1	-17.1	4.8	4.4	-0.0	6.6	-19.2	6.5	-1.3	3.6
+ Current Tax	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.4
+ Deferred Tax	0.5	-0.1	-0.2	-1.2	0.1	-0.1	1.9	2.6	-5.2	2.6	-0.6	1.0
Tax Expense	0.5	0.6	-0.1	-1.2	0.1	-0.1	2.0	2.6	-5.2	2.6	-0.3	1.4
Net Income	-8.3	-2.2	-2.0	-15.9	4.7	4.4	-2.0	4.0	-14.0	3.9	-1.0	2.2
+ Net Income — Continuing Ops	-8.3	-2.2	-2.0	-15.9	4.7	4.4	-2.0	4.0	-14.0	3.9	-1.0	2.2
+ Other Comprehensive Income	0.1	0.1	-0.7	0.0	-0.2	-0.1	1.4	-0.0	-0.0	0.5	5.0	0.4
Total Comprehensive Income	-8.2	-2.1	-2.7	-15.9	4.5	4.4	-0.6	3.9	-14.0	4.4	4.0	2.6
Net Income to Common	-8.3	—	-1.4	-15.8	4.8	4.5	-1.9	4.1	-13.9	4.0	0.5	2.3
Minority Interest	0.0	—	-0.6	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-1.5	-0.1
Per Share
Basic EPS	-1.35	-0.37	-0.23	-2.59	0.77	0.74	-0.31	0.66	-2.27	0.65	0.08	0.38
Diluted EPS	-1.35	-0.37	-0.23	-2.59	0.77	0.74	-0.31	0.66	-2.27	0.65	0.08	0.38
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	1.4	-0.0	-0.0	0.5	5.0	0.4
+ Items NOT to be Reclassified to P&L	0.2	0.1	-0.9	-0.1	-0.1	-0.1	0.3	-0.0	-0.0	0.6	1.5	0.5
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.1	-0.0	0.0	0.2	0.4	0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.0	0.0	-0.2	-0.0	-0.0	-0.0	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.0	0.0	-0.1	0.1	-0.1	—	1.2	—	—	—	3.9	0.0
Comprehensive Income — Owners of Parent	-8.3	-2.2	-2.1	-15.8	4.6	4.4	-0.5	4.0	-13.9	4.4	5.5	2.7
Comprehensive Income — Non-controlling Interests	0.1	0.1	-0.6	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-0.1	-1.5	-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	-1.35	-0.37	-0.23	-2.59	0.77	0.74	-0.31	0.66	-2.27	0.65	0.08	0.38
Diluted EPS — Continuing Operations	-1.35	-0.37	-0.23	-2.59	0.77	0.74	-0.31	0.66	-2.27	0.65	0.08	0.38
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	84.8	83.2	86.7	74.0	104.2	100.9	80.5	89.5	82.2	97.3	90.4	97.9
Gross Margin %	59.31	55.27	63.54	63.95	70.69	61.74	60.70	53.68	58.24	58.88	54.19	49.04
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-10.6	-4.4	-4.9	-19.8	2.0	1.6	-27.8	-4.8	-21.9	3.7	-4.0	0.8
− Exceptional Items (reconciliation)	2.8	2.8	2.7	2.7	2.8	2.8	27.7	11.3	2.7	2.8	2.7	2.7
Net Income Adj (tax-effected)	-11.1	-5.0	-4.6	-18.4	2.0	1.7	-29.7	-2.9	-16.0	2.2	-3.2	0.5
EPS Adj	-1.80	-0.84	-0.53	-3.01	0.32	0.28	-4.63	-0.48	-2.59	0.37	0.25	0.09
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1	6.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Panacea Biotec quarterly results

Panacea Biotec (NSE: PANACEABIO) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹2.3 crore, down 43.2% from ₹4.1 crore in Q1 FY26 and up 342.3% from ₹52 lakh in Q4 FY26. Revenue from operations was ₹200 crore, up 19.7% year on year and up 19.7% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 13 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹2.3 Cr−43.2% vs Q1 FY26+342.3% vs Q4 FY26
Q1 FY27 revenue: ₹200 Cr+19.7% vs Q1 FY26+19.7% vs Q4 FY26
Q1 FY27 operating margin: −1.1%+4.6 pts vs Q1 FY26+2.1 pts vs Q4 FY26
Q2 FY26 net loss (a year earlier): −₹13.9 CrRevenue ₹141 Cr
Q1 FY27 EPS (basic): ₹0.38

Questions

When will Panacea Biotec announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 14 November 2025.

What will Panacea Biotec's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net loss was ₹13.9 crore and revenue from operations ₹141 crore. The latest quarter, Q1 FY27, had a net profit of ₹2.3 crore and revenue of ₹200 crore.

What were Panacea Biotec's Q1 FY27 results?

Consolidated net profit was ₹2.3 crore, down 43.2% from ₹4.1 crore in Q1 FY26 and up 342.3% from ₹52 lakh in Q4 FY26. Revenue from operations was ₹200 crore, up 19.7% year on year and up 19.7% from the previous quarter.

How has Panacea Biotec's profit changed over the last four quarters?

Net profit by quarter: a loss of ₹13.9 crore in Q2 FY26, a profit of ₹4 crore in Q3 FY26, a profit of ₹52 lakh in Q4 FY26 and a profit of ₹2.3 crore in Q1 FY27. That is a combined loss of ₹7.1 crore over the four quarters. Revenue from operations: ₹141 crore, ₹165 crore, ₹167 crore and ₹200 crore.

What was Panacea Biotec's net profit in FY26?

Consolidated net profit was a loss of ₹5.4 crore in FY26 (April 2025–March 2026), narrower than the loss of ₹8.4 crore in FY25. It was a loss of ₹1.2 crore in FY24 and a loss of ₹33.8 crore in FY23.

What was Panacea Biotec's revenue in FY26?

Revenue from operations was ₹640 crore in FY26 (April 2025–March 2026), up 14.4% from ₹559 crore in FY25. It was ₹559 crore in FY24 and ₹460 crore in FY23: up 39.1% over three years, 11.6% a year on average.

Where do these Panacea Biotec figures come from?

From Panacea Biotec's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.